Shandong Weigao Blood Purification Products Co., Ltd. (SHA:603014)
China · Delayed Price · Currency is CNY 37.62
-0.06 (-0.16%)
At close: Apr 16, 2026
SHA:603014 Revenue
In the year 2025, Shandong Weigao Blood Purification Products had annual revenue of 3.77B CNY with 4.57% growth. Shandong Weigao Blood Purification Products had revenue of 1.03B in the quarter ending December 31, 2025, with 7.65% growth.
Revenue
3.77B
Revenue Growth
+4.57%
P/S Ratio
4.18
Revenue / Employee
n/a
Employees
n/a
Market Cap
15.74B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 3.77B | 164.70M | 4.57% |
| Dec 31, 2024 | 3.60B | 71.87M | 2.03% |
| Dec 31, 2023 | 3.53B | 106.03M | 3.09% |
| Dec 31, 2022 | 3.43B | 515.59M | 17.71% |
| Dec 31, 2021 | 2.91B | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Autobio Diagnostics | 4.22B |
| Cofoe Medical Technology | 3.39B |
| MGI Tech | 2.78B |
| Double Medical Technology | 2.48B |
| SonoScape Medical | 2.07B |
| Jafron Biomedical | 2.04B |
| MeHow Innovative | 1.63B |
| Shandong Weigao Orthopaedic Device | 1.52B |